Genomic predictors of survival in patients with high-grade urothelial carcinoma of the bladder. - Wikidata - awgldk - TriplyDB

Genomic predictors of survival in patients with high-grade urothelial carcinoma of the bladder.

Genomic predictors of survival in patients with high-grade urothelial carcinoma of the bladder.

http://www.wikidata.org/entity/Q35034441

about

Mediator kinase module and human tumorigenesis Mutations of Chromatin Structure Regulating Genes in Human Malignancies.Somatic Copy Number Abnormalities and Mutations in PI3K/AKT/mTOR Pathway Have Prognostic Significance for Overall Survival in Platinum Treated Locally Advanced or Metastatic Urothelial Tumors The fascinating story of urine examination: From uroscopy to the era of microscopy and beyond.Extreme Outlier Analysis Identifies Occult Mitogen-Activated Protein Kinase Pathway Mutations in Patients With Low-Grade Serous Ovarian Cancer.Genomic Characterization of Upper Tract Urothelial Carcinoma High efficacy of intravesical treatment of metformin on bladder cancer in preclinical model.Summary and Recommendations from the National Cancer Institute's Clinical Trials Planning Meeting on Novel Therapeutics for Non-Muscle Invasive Bladder Cancer Coexistence of YWHAZ amplification predicts better prognosis in muscle-invasive bladder cancer with CDKN2A or TP53 loss.Identification of key pathways and genes influencing prognosis in bladder urothelial carcinoma Targeted therapies in bladder cancer: an overview of in vivo research.Targeting Signaling Transduction Pathways in Bladder Cancer.Toward personalized management in bladder cancer: the promise of novel molecular taxonomy.Chromosomal abnormalities and molecular landscape of metastasizing mucinous salivary adenocarcinoma.ARF Confers a Context-Dependent Response to Chemotherapy in Muscle-Invasive Bladder Cancer DNA Damage Response and Repair Gene Alterations Are Associated with Improved Survival in Patients with Platinum-Treated Advanced Urothelial Carcinoma.MLL3/MLL4/COMPASS Family on Epigenetic Regulation of Enhancer Function and Cancer.The Emergence of Precision Urologic Oncology: A Collaborative Review on Biomarker-driven Therapeutics.Massive parallel sequencing of solid tumours - challenges and opportunities for pathologists.Biomarkers for precision medicine in bladder cancer.The NF1 gene in tumor syndromes and melanoma.EZH2 in Cancer Progression and Potential Application in Cancer Therapy: A Friend or Foe?Next-generation Sequencing of Nonmuscle Invasive Bladder Cancer Reveals Potential Biomarkers and Rational Therapeutic Targets.BcCluster: A Bladder Cancer Database at the Molecular Level.Next-generation sequencing of urine specimens: A novel platform for genomic analysis in patients with non-muscle-invasive urothelial carcinoma treated with bacille Calmette-Guérin.Genomic characterization of response to chemoradiation in urothelial bladder cancer.Precision medicine for urothelial bladder cancer: update on tumour genomics and immunotherapy.Functional Impact of Chromatin Remodeling Gene Mutations and Predictive Signature for Therapeutic Response in Bladder Cancer.Development of a personalized therapeutic strategy for ERBB-gene-mutated cancers.Role of Radical Cystectomy in Non-Organ Confined Bladder Cancer: A Systematic Review.Small cell carcinomas of the bladder and lung are characterized by a convergent but distinct pathogenesis.HumanMethylation450K Array-Identified Biomarkers Predict Tumour Recurrence/Progression at Initial Diagnosis of High-risk Non-muscle Invasive Bladder Cancer.Somatic mutation of the cohesin complex subunit confers therapeutic vulnerabilities in cancer.The crucial role of multiomic approach in cancer research and clinically relevant outcomes.Bladder Cancer: New Insights into Its Molecular Pathology.Molecular characterization and integrative genomic analysis of a panel of newly established penile cancer cell lines.Urinary Exosomal and cell-free DNA Detects Somatic Mutation and Copy Number Alteration in Urothelial Carcinoma of Bladder ARID1A-deficiency in urothelial bladder cancer: No predictive biomarker for EZH2-inhibitor treatment response?UCA1 overexpression is associated with less aggressive subtypes of bladder cancer

P2860

Q26800203-F3C94DEA-86D4-455F-921B-D8249AEDD6A2 Q33600399-A8A4BD7C-6DCA-446A-A6B5-E337141AE921 Q35651546-3446E098-0B03-4333-A5E8-2B7D6C486639 Q35782652-2BA0D8F2-8D3C-433C-A9FE-CF12A66E5DE0 Q36346641-B39DFA47-658D-4394-A971-2973DEE4E7A0 Q36362571-3BF78A3C-1DF9-452B-AB65-1ECA483D8A12 Q36962520-4CB23A80-E300-4DFE-9387-8C6112BBB4D7 Q37053820-B6928301-FC19-45B5-854E-7BCBED4DD434 Q37376373-6BED4722-81C1-4408-92E6-86B92FCB7168 Q38435311-0ACB92B7-5841-4F59-9ECA-5A94C08EC400 Q38590471-2172D8A2-BE53-4E31-B0D4-EDA58FE851E7 Q38608540-59344E9E-F0A9-4563-8909-2222C7A5FA59 Q38692457-4991900A-51A1-462D-9CBA-FAB9D4D0D629 Q38714341-D7B634BA-D992-4655-AE9C-50BA458EC82D Q38721568-4EFA19E6-79C2-452A-A989-F4109337AD4F Q38764205-1B679D82-F058-46FE-B758-1491152DA597 Q38800948-CAC708DB-BBAB-4F28-BB43-D1FC28239FD5 Q38827251-3A1507D2-039D-4358-9D20-9371E73C9A43 Q38828314-20E58DED-3F04-46B5-B823-31DEE0EBC76D Q39023158-5C9D323F-4890-4E32-9444-73033EA2B5BF Q39076849-0B76AB85-5235-4549-88DA-945631E8F84A Q39340502-88CD21D3-3179-4469-9D4F-5719BF6FDBF9 Q39352697-2FD28D45-9070-4F52-9A9D-82A5324FD1F7 Q39634042-98F58480-3018-4968-A83D-04F101DABCFD Q40275671-B661F83A-AD43-469A-AD0C-A46C5544E655 Q44338887-8C80ECF7-7C92-4ED7-866E-4BFB5614BA37 Q47406496-46F9B3C6-D3EE-47B4-A5F1-C9C72968E771 Q47712149-DFF639A3-2031-41A8-BE73-FC467173AC84 Q48138303-B9577AB4-D13B-416E-A75F-676BA456CFA2 Q49420756-1481366B-5D9F-428E-BA96-2BCCE280F958 Q49586740-9C094B35-18F8-4A2C-8C58-03C3750B8602 Q49988036-240A9F66-4AE4-4691-B9C0-D61F681B2326 Q52323640-AF7796D7-6E06-4E85-B18E-D5D71838E255 Q52363678-BDE19E13-9CF4-4CDA-8C3E-3DFEA53CECD2 Q52609673-6E0B6A8E-0265-4E69-AF0A-E70E3CB61F99 Q55185781-65D6711F-1A91-44B3-9147-CE36441227CD Q57050171-E8685846-B4B4-49D3-BEFA-185E2341915E Q57167864-44D52786-D961-4841-993B-AABA66E4C3FA Q58753654-DE48FB63-0417-4E0E-8F9A-108A8C410BF6

P2860

Genomic predictors of survival in patients with high-grade urothelial carcinoma of the bladder.

http://www.wikidata.org/entity/Q35034441

description

2014 nî lūn-bûn

@nan

2014 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Genomic predictors of survival ...... lial carcinoma of the bladder.

@ast

Genomic predictors of survival ...... lial carcinoma of the bladder.

@en

type

label

Genomic predictors of survival ...... lial carcinoma of the bladder.

@ast

Genomic predictors of survival ...... lial carcinoma of the bladder.

@en

prefLabel

Genomic predictors of survival ...... lial carcinoma of the bladder.

@ast

Genomic predictors of survival ...... lial carcinoma of the bladder.

@en

P1433

Q35034441-B030BF29-C2A1-4B14-AAAB-D995716C63A3

P1476

Q35034441-7AB8BB44-DB5D-4C52-875A-1606455A9B6D

P2093

Q35034441-283588F0-8B5E-4BC2-BA51-89FA420C4177

Q35034441-49C05636-0D25-4832-BCBA-87321918A30E

Q35034441-4BC9B039-A648-42D5-8986-A7438B451EF4

Q35034441-591BCC25-BC91-490E-897F-86546BA3684B

Q35034441-62A45327-8F80-4F56-A577-F4895E2A0708

Q35034441-71D45A20-6735-40D6-92A7-4C3DE22E5515

Q35034441-92674890-0BEF-4379-A2EA-1400498ABA9A

Q35034441-9BF5CC5F-F83C-4704-90C5-7FE9A52658A6

Q35034441-9C353E7C-C0D5-4F60-83A3-2BA81D0D7597

Q35034441-A0570A8D-833F-4346-9887-0189BBC13B22

P2860

Q35034441-33843780-CA68-4EB6-8A1D-6085ED9CA8F0

Q35034441-485960D9-F9B8-4C83-99D3-625CAEC0CF08

Q35034441-4A217314-9D9B-4B1F-A186-B9B42CC7AE51

Q35034441-521E08EF-BB5A-4F5B-B638-8BF1B088F473

Q35034441-68F079DE-E4E7-416A-94BB-FB3B044112EF

Q35034441-8A4B0C54-4920-4927-B203-058B291B6044

Q35034441-A8F00EAC-2B94-4B1C-8FCA-6357F11926E3

Q35034441-D6B985D5-F7A6-46EF-98D2-B334AE0BD442

Q35034441-DA7BAA4D-FEE9-4B64-8505-B0DFC5E25632

Q35034441-EA951D95-C8A0-4148-8B64-88E66489B05C

P304

Q35034441-CF7C2732-9650-42EE-A6CC-7EC12C6C0656

P31

Q35034441-44695D1C-C98A-4866-BF41-4C948A120EE6

P356

Q35034441-B0E8E134-D007-4466-BD5B-8F52EEA5766F

P407

Q35034441-795D123A-1869-48D7-83E6-F515D2E11714

P433

Q35034441-C7224A46-CE44-4232-9DF2-818046A5A29B

P478

Q35034441-47CE0F0A-F8B6-4017-BD8A-2D469A5E6694

P50

Q35034441-65964405-073F-40D0-9D9C-6EA43F3D0CCD

Q35034441-70D7BFFC-80C2-420D-938B-B0437E5D3E68

Q35034441-8ED1E452-213F-4101-A415-316D993F7688

Q35034441-C1BB850C-EAE4-4B82-9C49-B2A1C36ACA5E

Q35034441-D5B48388-5BFB-454C-BD5A-98F64A52E8EE

Q35034441-DCFFC0DC-D6A2-4F7F-8C27-9E149C182730

P577

Q35034441-A583F06A-7505-4294-8125-2C56A6900C09

P698

Q35034441-A3FE7E68-7A1D-4B07-B0BA-F01BA2F0E061

P932

Q35034441-7DB63DA3-2D85-4C0E-9996-E3BE858395C8

P356

J.EURURO.2014.06.050

P1433

European Urology

P1476

Genomic predictors of survival ...... lial carcinoma of the bladder.

@en

P2093

Alyssa M Yee

http://www.w3.org/2001/XMLSchema#string

Arony Sun

http://www.w3.org/2001/XMLSchema#string

David B Solit

http://www.w3.org/2001/XMLSchema#string

Dean F Bajorin

http://www.w3.org/2001/XMLSchema#string

Emily C Zabor

http://www.w3.org/2001/XMLSchema#string

Gopa Iyer

http://www.w3.org/2001/XMLSchema#string

Irina Ostrovnaya

http://www.w3.org/2001/XMLSchema#string

John P Sfakianos

http://www.w3.org/2001/XMLSchema#string

Michael F Berger

http://www.w3.org/2001/XMLSchema#string

Philip H Kim

http://www.w3.org/2001/XMLSchema#string

P2860

Comprehensive molecular characterization of urothelial bladder carcinoma

High-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing

Prevalence and co-occurrence of actionable genomic alterations in high-grade bladder cancer.

Recurrent inactivation of STAG2 in bladder cancer is not associated with aneuploidy.

Frequent truncating mutations of STAG2 in bladder cancer.

Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder.

PIK3CA mutation associates with improved outcome in breast cancer.

PIK3CA mutation is associated with a favorable prognosis among patients with curatively resected esophageal squamous cell carcinoma.

A molecular taxonomy for urothelial carcinoma.

Whole-genome and whole-exome sequencing of bladder cancer identifies frequent alterations in genes involved in sister chromatid cohesion and segregation.

P304

198-201

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.EURURO.2014.06.050

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

67

http://www.w3.org/2001/XMLSchema#string

P50

Jonathan E Rosenberg

Nikolaus Schultz

Hikmat Al-Ahmadie

Bernard H Bochner

P577

2014-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25092538

http://www.w3.org/2001/XMLSchema#string

P932

4312739

http://www.w3.org/2001/XMLSchema#string